Experimental Immunotherapy Shows High Complete Response Rate in High-Risk Bladder Cancer

An international Phase III study (BOND-003 Cohort C) published in The Lancet Oncology reported positive findings for cretostimogene grenadenorepvec, an experimental immunotherapy for patients with BCG-unresponsive, non-muscle-invasive bladder cancer. The study demonstrated a 75% complete response rate, helping many patients avoid bladder removal surgery and maintain quality of life.